WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318695
CAS#: 959-24-0 (HCl)
Description: Sotalol HCl is an adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. Sotalol HCl is a compound categorized with class III antiarrhythmic activity with a mechanism of action that prolongs the action potential and refraction of cardiac tissue through non-selective yet potent β-adronergic blocking activity.
Hodoodo Cat#: H318695
Name: Sotalol HCl
CAS#: 959-24-0 (HCl)
Chemical Formula: C12H21ClN2O3S
Exact Mass: 0.00
Molecular Weight: 308.820
Elemental Analysis: C, 46.67; H, 6.85; Cl, 11.48; N, 9.07; O, 15.54; S, 10.38
Related CAS #: 959-24-0 (HCl) 3930-20-9 (free)
Synonym: Sotalol Hydrochloride; Sotalol HCl; Betapace; Betapace AF; Sotacor; Sotalol Monohydrochloride; Darob; Knoll Pharmaceutical Brand of Sotalol;
IUPAC/Chemical Name: N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide;hydrochloride
InChi Key: VIDRYROWYFWGSY-UHFFFAOYSA-N
InChi Code: InChI=1S/C12H20N2O3S.ClH/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17;/h4-7,9,12-15H,8H2,1-3H3;1H
SMILES Code: CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O.Cl
Appearance: White to off-white solid powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 308.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Broux B, De Clercq D, Decloedt A, De Baere S, Devreese M, Van Der Vekens N, Ven S, Croubels S, van Loon G. Pharmacokinetics of intravenously and orally administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left ventricular systolic function. Vet J. 2016 Feb;208:60-4. doi: 10.1016/j.tvjl.2015.09.021. Epub 2015 Oct 1. PubMed PMID: 26670333.
2: Sidhom MB, Rivera N, Almoazen H, Taft DR, Kirschenbaum HL. Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations. Int J Pharm Compd. 2005 Sep-Oct;9(5):402-6. PubMed PMID: 23925139.
3: Wang WH, Zhao GS, Jiang WL, Zuo AX, Bi HT. [Determination of sotalol hydrochloride by reversed-phase high performance liquid chromatography]. Se Pu. 2000 Mar;18(2):178-80. Chinese. PubMed PMID: 12541604.
4: Telichowski A, Banasiak W, Wiech K, Zeborowski J, Pieróg M, Ponikowski P, Kałka D, Lacheta W, Fuglewicz A, Telichowski C. [The effect of sotalol hydrochloride therapy on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. Pol Merkur Lekarski. 1996 Nov;1(5):303-9. Polish. PubMed PMID: 9273201.
5: Bobak J, Banasiak W, Telichowski A, Ponikowski P, Kałka D, Jagielski J, Telichowski C. [The effects of long-term treatment of sotalol hydrochloride on time and frequency domain parameters of signal averaged electrocardiogram in patients with ischemic heart disease]. Pol Arch Med Wewn. 1996 Apr;95(4):289-98. Polish. PubMed PMID: 8755834.
6: Herrmann R, Kleinbloesem CH. [Testing of bioequivalence of a new sotalol hydrochloride preparation in comparison to a standard formulation]. Arzneimittelforschung. 1995 Aug;45(8):849-52. German. PubMed PMID: 7575745.
7: Herrmann R, Kleinbloesem CH. [Bioequivalence of a new tablet formulation of sotalol hydrochloride in comparison to a standard preparations]. Arzneimittelforschung. 1994 May;44(5):589-92. German. PubMed PMID: 8024627.
8: Porterfield JG, Porterfield LM. Sotalol hydrochloride (Betapace): a new antiarrhythmic drug. Am J Crit Care. 1994 Jan;3(1):80. PubMed PMID: 8118498.
9: Dunnington CS. Sotalol hydrochloride (Betapace): a new antiarrhythmic drug. Am J Crit Care. 1993 Sep;2(5):397-406. Review. PubMed PMID: 8220672.
10: Weikel JH Jr, Kelly WA. Tumorigenicity assays of sotalol hydrochloride in rats and mice. J Clin Pharmacol. 1979 Aug-Sep;19(8-9 Pt 2):591-604. PubMed PMID: 489774.
11: Ward DE, Camm AJ, Spurrell RA. The acute cardiac electrophysiological effects of intravenous sotalol hydrochloride. Clin Cardiol. 1979 Jun;2(3):185-91. PubMed PMID: 509798.
12: Gajendragadkar SV, Clarke WE. Comparison of sotalol hydrochloride and methyldopa in essential hypertension. J Int Med Res. 1977;5(4):233-5. PubMed PMID: 881095.
13: Gabriel R. Control of hypertension with single daily doses of sotalol hydrochloride. Curr Med Res Opin. 1976-1977;4(10):739-42. PubMed PMID: 1052165.
